Rheumatoid Arthritis Update: Current & New Therapeutics
Presented by The Johns Hopkins University School of Medicine. Supported through an educational grant from Roche Pharmaceuticals.
Program Overview
This five-segment program will begin with a brief overview of critical mediators in Rheumatoid Arthritis (RA), and how they impact upon the pathogenesis and treatment options. The expert-panel discussion will highlight current key players in the RA inflammatory cascade and how they mediate joint destruction. The state of current therapy with conventional and biological disease-modifying antirheumatic drugs, and the importance of early diagnosis and rapid initiation of treatment will be discussed. Methods of evaluating therapeutic responses to treatment, and strategies for escalating current doses or adding additional therapy, or changing to a new class of therapeutic agents will be presented.
Program Format
CME-certified professional education program: 1-hour online program
Estimated time to complete this educational activity: 1 hour
Intended Audience
This activity has been designed for rheumatologists and other healthcare professionals managing patients with Rheumatoid Arthritis.
There are no prerequisites
Release and Expiration Dates
Release March 28, 2008
Expiration March 28, 2009
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™.
Responsibility Statement
The Johns Hopkins University School of Medicine takes responsibility for the content, quality and scientific integrity of this CME activity.
Learning objectives
At the conclusion of this activity, participants should be able to:
- Review critical mediators in the pathogenesis of rheumatoid arthritis including inflammatory, autoimmune and genetic factors.
- Describe the immunological basis for therapy with newer classes of therapeutic agents including efficacy, safety and tolerability profiles.
- Discuss issues related to sub-optimal responses or failure of conventional and biologic disease-modifying agents used in the treatment of rheumatoid arthritis.
- Outline treatment strategies used to address inadequate responses or treatment failures observed in patients with rheumatoid arthritis.
Evaluation/ Post-test
Participants must document the amount of time spent and must receive a grade of 70% or above to receive a CME certificate. Certificates will be sent in 6-8 weeks.
Privacy Statement
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. The Johns Hopkins University School of Medicine CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet-based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine's CME program. Continuing Medical Education collects only the information necessary to provide you with the services that you request.
Faculty
Clifton O. Bingham III, MD
Assistant Professor of Medicine
Johns Hopkins University
Clifton Bingham III, MD, is an assistant professor of medicine at the Johns Hopkins University. He is director of the Johns Hopkins Rheumatology Clinics, a member of the Arthritis Center faculty, and director of the Johns Hopkins arthritis website. He was previously on faculty at the New York University Hospital for Joint Diseases, where he founded and directed the Seligman Center for Advanced Therapeutics.
Dr. Bingham received his MD from Columbia University, where he also completed internship and residency training in Internal Medicine. He trained in Clinical Rheumatology, and in Allergy and Clinical Immunology at the Brigham and Women’s Hospital in Boston. He completed additional postdoctoral fellowship training at Harvard Medical School and served as an attending Rheumatologist and Allergist/Immunologist at Brigham and Women’s and at Massachusetts General Hospital. He joined the faculty at NYU Hospital for Joint Diseases in 1999 and was recruited to the faculty at Johns Hopkins in January 2005.
Dr. Bingham has served on an expert panel for clinical research at the NIH-NIDCR, an NIH-NIAMS special emphasis panel study section, and has served as an NIH-NIDCR reviewer and a reviewer for rheumatology journals. He is active in the American College of Rheumatology,
Dr. Bingham’s clinical interests include: novel therapeutic agents in the treatment of rheumatoid arthritis, osteoarthritis, chronic autoimmune urticaria, and immunologic function and susceptibility to infection in patients with inflammatory arthritis. His current research program focuses on oral health in inflammatory arthritis, risk factors for progression in osteoarthritis, and defining disease phenotypes related to therapeutic responses in RA and OA.
John J. Cush, MD
Professor of Medicine and Rheumatology
Baylor University Medical Center
John J. Cush, MD, received his undergraduate degree from St. Johns University and his medical degree from St. Georges University School of Medicine. After completing an internal medicine residency at Coney Island Hospital in New York City, Dr. Cush finished his rheumatology training and fellowship at University of Texas Southwestern Medical School and Parkland Memorial Hospital. He has been on the faculty at Southwestern Medical School since 1987, where he is a clinical professor of internal medicine. He is the director of clinical rheumatology for the Baylor Research Institute and a professor of medicine and rheumatology at Baylor University Medical Center in Dallas, Texas.
Dr. Cush is devoted to patient care, medical education and novel drug research for the rheumatic diseases. He has been published in more than 100 medical and scientific publications and has written two textbooks on rheumatology: Rheumatology: Diagnosis and Therapeutics (2nd edition, Lippincott, Williams & Wilkins, 2005), and Rheumatoid Arthritis: Early Diagnosis and Treatment (2nd edition, Professional Communications, 2008).
Dr Cush is the recipient of numerous awards and distinctions, including the Robert B. Hingson Humanitarian Award (1988), Intern of the Year (1985), Teacher of the Year (1999), Best Doctors in America (1996, 1998, 2001-2002) and Best Doctors in Dallas (1998-2007). He has held numerous leadership positions for the National Arthritis Foundation and the American College of Rheumatology and has served on the Arthritis Advisory Committee for the Food and Drug Administration.
Yusuf Yazici, MD
Assistant Professor of Medicine
New York University School of Medicine
Yusuf Yazici, MD, is an assistant professor of medicine at the New York University School of Medicine. Dr. Yazici is also the director of the Seligman Center for Advanced Therapeutics and director of the Behcet’s Syndrome Evaluation, Treatment and Research Center at NYU Hospital for Joint Diseases.
Dr. Yazici earned his medical degree from Cerrahpasa Medical Faculty of Istanbul University in Istanbul, Turkey. He completed his internship and residency at Creighton University in Nebraska and his fellowship in rheumatology at the Hospital for Special Surgery of Weill Medical College, Cornell University.
His areas of interest are patient reported outcomes, rheumatoid arthritis, early arthritis, Behcet’s syndrome, database and registry management, and monitoring of arthritis patients in regard to clinical response and adverse events related to treatment.
Faculty Disclosures
Full Disclosure Policy Affecting CME Activities
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
Dr. Clifton O. Bingham III, (Chair) Type of financial relationship:
Grants: Genentech, Wyeth
Consulting: Abbott, Amgen, Genentech, Merck, Novartis, Nicox, Targeted Genetics,
Other financial or material support (education support): Abbott, Amgen, Bristol-Myers Squibb, Centocor, Genentech
Dr. John J. Cush Type of financial relationship:
Clinical Investigator: Genentech, Pfizer, Targeted Genetics, UCB, Roche
Consulting/Honorarium: Abbott, Amgen, Centocor, Genentech, Novartis, Pfizer, UCB, Roche, Wyeth
Dr. Yusuf Yazici Type of financial relationship:
Grants: Genentech, Bristol-Myers Squibb, Pfizer, Roche
Consulting/ Honorarium: Bristol-Myers Squibb, Centocor, Pfizer, Roche
Speaker Bureau: Bristol-Myers Squibb, Pfizer
Off-Label Discussion
No faculty member has indicated that their presentation will include information on off-label products.
Disclaimer
The opinions and recommendations expressed by faculty and other experts, whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Internet Policy
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University School of Medicine CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine's CME program. CME collects only the information necessary to provdie you with the services you request.
Program
© 2008 the Johns Hopkins University School of Medicine. All rights reserved.
In collaboration with Healthology Inc.
ACR 2007 Highlights
Pathophysiology 2007